Bromocriptine in Parkinson's disease: pleuropulmonary toxicity

The authors report a case of pleuro-pulmonary fibrosis after 9 months of high dose bromocriptine therapy for the treatment of Parkinson's disease. When the drug was stopped there was a significant improvement of the clinical state with complete regression of chest pain and dyspnea of effort. Th...

Full description

Saved in:
Bibliographic Details
Published inAnnales de médecine interne Vol. 136; no. 5; p. 416
Main Authors Douvier, J J, Vergeret, J, Taytard, A, Brottier, E, Domblides, P, Dubos, F, Freour, P
Format Journal Article
LanguageFrench
Published France 1985
Subjects
Bromocriptine - adverse effects
Humans
Male
Middle Aged
Parkinson Disease - drug therapy
Pleural Diseases - chemically induced
Pleural Diseases - diagnosis
Pulmonary Fibrosis - chemically induced
Pulmonary Fibrosis - diagnosis
Online AccessGet more information

Cover

More Information
Summary:The authors report a case of pleuro-pulmonary fibrosis after 9 months of high dose bromocriptine therapy for the treatment of Parkinson's disease. When the drug was stopped there was a significant improvement of the clinical state with complete regression of chest pain and dyspnea of effort. The major inflammatory biological syndrome disappeared completely. Chest X-rays showed partial improvement with signs of pleural pneumonitis. The results of ventilatory and respiratory function tests stabilised. After one year follow-up, the causal relationship of this iatrogenic pathology has therefore been established. The initial diagnostic problems are stressed, particularly with respect to malignant disease (mesothelioma) when there has been exposure to asbestos, as in our case. The early stages must be carefully looked for so as to prevent fibrosing complications. The presence of immune complexes in our case could indicate immuno-allergic mechanism.
ISSN:0003-410X